Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of ICT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2020-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Idiopathic thrombocytopenic purpura (ITP) is the most frequent auto-immune cytopenia. There is no specific biological marker and the diagnosis often results from the exclusion of other differential diagnoses, notably inherited thrombocytopenia.

Recent studies have reported an original platelet destruction mechanism in ITP, by antibody-mediated desialylation of membrane proteins. The detection of platelet sialylation can be readily achieved using flow cytometry. This could provide a new biomarker of ITP, useful to ascertain a diagnosis of ITP and guide towards proper patient management.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnostic of Chronic Thrombocytopenia

NCT04071496

Congenital Thrombocytopenia Chronic Idiopathic Thrombocytopenic Purpura

COMPLETED

Association of Platelet Parameters With Bleeding Severity in Children With ITP

NCT03810352

Immune Thrombocytopenia

COMPLETED

Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura

NCT04056507

Immune Thrombocytopenic Purpura Splenectomy; Status

COMPLETED

Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura

NCT05093257

Immune Thrombocytopenic Purpura

UNKNOWN

The Outcome of the Thrombopoietin Receptor Agonists in Pediatric Patient With Persistent or Chronic ITP Unresonsive to Steroids

NCT06568913

Persistent or Chronic ITP Not Respnding to Steroids

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Thrombocytopenic Purpura

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Idiopathic thrombocytopenic purpura

non interventional study

Intervention Type OTHER

non interventional study

non immunological thrombocytopenia

patient with constitutive thrombocytopenia, myelodysplastic syndrome, or chemotherapy-induced thrombocytopenia

non interventional study

Intervention Type OTHER

non interventional study

without thrombocytopenia

non interventional study

Intervention Type OTHER

non interventional study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

non interventional study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (\>18yo) with a diagnosis of ITP (primary acute, persisting or chronical)
* Adult patients (\>18yo) with a diagnosis of non immunological thrombocytopenia (constitutive thrombocytopenia, myelodysplastic syndrome, chemotherapy-induced thrombocytopenia)
* Adult patients (\>18 yo) without thrombocytopenia
* Enrolled in a Social Security system
* Having provided informed consent

Exclusion Criteria

* Minor patients (\<18 yo)
* Enrolled in another clinical study
* Having received corticosteroids or polyvalent immunoglobulins in the past 4
* weeks or anti-platelet therapy or NSAID during the past 7 days
* Having received platelet transfusion in the past fortnight
* With proven iron deficiency
* With drug-induced immune-allergic thrombocytopenia.
* Pregnant and breastfeeding women,
* guardian patients, will be excluded from this population.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No